Drugs / Moderna Bivalent mRNA vaccine
Moderna Bivalent mRNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05556720 | Dec 2022 → Jun 2026 overdue | B-cell chronic lymphocytic leukemia, HIV infectious disease, disease related to solid organ transplantation, plasma cell myeloma | Monash University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moderna Bivalent mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556720 ↗ |
| Modality | Messenger RNA (mRNA) | “contains 50 micrograms of messenger ribonucleic acid (mRNA) (Andusomeran)” NCT05556720 ↗ |